<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00817986</url>
  </required_header>
  <id_info>
    <org_study_id>XP-B-083</org_study_id>
    <nct_id>NCT00817986</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of XP19986 in Subjects With Acute Back Spasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indivior Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indivior Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate safety and tolerability of arbaclofen placarbil
      sustained release tablets taken every 12 hours compared to placebo in subjects with acute
      back spasms in the lumbar region.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>14 Days</time_frame>
    <description>Safety was assessed based on the incidence, intensity and relationship of treatment emergent AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pain severity score using the VAS</measure>
    <time_frame>4 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Back Pain</condition>
  <arm_group>
    <arm_group_label>Arbaclofen placarbil 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arbaclofen placarbil 20 mg, BID, for 14 days including the taper period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Arbaclofen placarbil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arbaclofen placarbil 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arbaclofen placarbil 30 mg, BID, for 14 days including the taper period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arbaclofen placarbil 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arbaclofen placarbil 40 mg, BID, for 14 days including the taper period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arbaclofen placarbil, 20 mg</intervention_name>
    <description>tablets</description>
    <arm_group_label>Arbaclofen placarbil 20 mg</arm_group_label>
    <other_name>XP19986 SR3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablets</description>
    <arm_group_label>Placebo for Arbaclofen placarbil</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arbaclofen placarbil, 30 mg</intervention_name>
    <description>tablets</description>
    <arm_group_label>Arbaclofen placarbil 30 mg</arm_group_label>
    <other_name>XP19986 SR3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arbaclofen placarbil, 40 mg</intervention_name>
    <description>tablets</description>
    <arm_group_label>Arbaclofen placarbil 40 mg</arm_group_label>
    <other_name>XP19986 SR3 tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acute moderate to severe muscle spasms in the lumbar region, as indicated by a minimum
             Visual Analog Scale pain severity score of 4.0 cm, beginning either:

               -  within four days prior to screening for subjects who do not require a 24-hour
                  washout

             Or

               -  within three days for subjects who require a 24-hour washout

          2. Willing to discontinue all analgesics (e.g. NSAIDS, COX-2 inhibitors, acetaminophen),
             aspirin &gt;81 mg/day, short-acting muscle relaxants (i.e. carisoprodol, Soma®), and
             herbal remedies for pain at least 24 hours prior to first dose and to refrain from use
             during the study (cardio-protective doses of aspirin ≤ 81 mg /day are allowed).

        Exclusion Criteria:

          1. Clinically significant abnormal neurological history or examination at screening
             (excluding back spasm), including lumbar radicular symptoms, spinal stenosis, foot
             drop, herniated nucleus pulposus, or other structural defects

          2. Subjects with back spasm related to major trauma to the region

          3. Subjects with muscle spasms due to a work-related injury or subjects involved in any
             injury-related litigation

          4. Subjects using any of the following medications at screening:

               -  Opioids, both short- and long-acting including but not limited to: morphine,
                  fentanyl patch, oxycodone, tramadol)

               -  benzodiazepines, such as valium and lorazepam

               -  cyclobenzaprine containing drugs (e.g., Flexeril, Amrix)

               -  carisoprodol (e.g., Soma®) within 24 hours of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Indivior Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Litchfield Park</city>
        <state>Arizona</state>
        <zip>85340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlanger</city>
        <state>Kentucky</state>
        <zip>41018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <zip>07732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2009</study_first_submitted>
  <study_first_submitted_qc>January 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2009</study_first_posted>
  <disposition_first_submitted>September 8, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 10, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 14, 2010</disposition_first_posted>
  <last_update_submitted>September 9, 2016</last_update_submitted>
  <last_update_submitted_qc>September 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute back pain in the lumbar region</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arbaclofen placarbil</mesh_term>
    <mesh_term>Baclofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

